Pharvaris BV Earnings

The next earnings date for Pharvaris BV is April 14, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Pharvaris BV Earnings

Report DateEstimated Earnings Per Share
04/14/2026$-0.64

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Pharvaris BV Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/05/2025---$0100.00%
08/08/2025---$0100.00%
08/01/2025---$0100.00%
07/25/2025---$0100.00%
04/07/2025---$-0.85-2.78%
11/14/2024---$-0.77-27.42%
08/05/2024Before Market$-0.60-3.45%
05/08/2024After Market$-0.527.14%
03/06/2024Before Market$-0.82-41.38%
11/02/2023Before Market$-0.583.33%
08/07/2023Before Market$-0.633.08%
04/05/2023Before Market$-1.17-80.00%
12/08/2022Before Market$-0.2560.32%
09/12/2022Before Market$-0.3833.33%
05/11/2022Before Market$-0.482.04%
03/29/2022Before Market$-0.0987.32%
11/10/2021Before Market$-0.397.14%
07/30/2021Before Market$-0.94-141.03%
04/29/2021After Market$-2.18-83.19%
02/09/2021After Market$-2.65-90.65%
12/31/2019---$-0.80---

More About Pharvaris BV

Country
USA
Full Time Employees
118

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris BV Earnings” Can Refer to the Pharvaris BV Earnings Date

Some people say “Pharvaris BV earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Pharvaris BV position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Pharvaris BV Stock on the Earnings Date

If you own Pharvaris BV stock (PHVS) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Pharvaris BV might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Pharvaris BV shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Pharvaris BV Earnings

You can contact us any time if you would like to ask questions about Pharvaris BV earnings or anything else related to the stock market.